THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER -1 study, ...
In an effort to help more patients bring down the risk of heart attack and stroke, Amgen recently made Repatha available in the United States (U.S.) at a 60 percent reduced list price to address ...
(Reuters) - Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this ...
Amgen stock (NASDAQ NDAQ: AMGN) has seen a substantial 23% rise this year, far better than the broader S&P500 index, which is down 16%. However, in the longer term, AMGN stock is up 42% from levels ...
So far, this year's J.P. Morgan Healthcare Conference has been the go-to event for pharmaceutical companies to share their new research pals. Amgen is adding to the camaraderie with a $75 million ...
Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...
DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback